Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Professor Lakhal-Littleton, an Oxford BHF CRE PI, and her team have investigated non-anaemic iron deficiency in cardiovascular medicine due to its association with a range of adverse effects in various conditions. Lessons learned could ultimately translate into benefits for patients with other conditions such as chronic kidney disease, chronic obstructive pulmonary disease and cancer.

Professor Samira Lakhal-Littleton

In the past decade, the Lakhal-Littleton team have uncovered the mechanisms and importance of iron regulation in different cells within the cardiovascular system1-5 . More recently, their discoveries have challenged accepted notions about how the heart handles iron from intravenous iron therapy in patients6. The current review harnesses this growing understanding to dissect, at a more mechanistic level, the adverse impact of iron deficiency in heart failure patients, and the mixed success of iron supplementation therapies in this context7. It also highlights untapped opportunities for improving the management of iron deficiency in heart failure.

  1. DOI: 10.1161/ATVBAHA.123.319224
  2. DOI: 10.3389/fcvm.2020.616920
  3. DOI: 10.1073/pnas.1822010116
  4. DOI: 10.1073/pnas.1422373112
  5. DOI: 10.7554/eLife.19804
  7. DOI: 10.1038/s41569-024-00988-1  (fulltext available on

Read more about the research being done by the Lakhal-Littleton group here.

Read the full article at